Published Articles

Dabigatran reversal confirmed in real world emergencies

The reversal agent for dabigatran can rapidly switch off the anticoagulant effect of the novel oral anticoagulant when required in emergency situations, a real world study has shown.
12 July 2017

One-third of patients give up on DOACs after six months

As many as one in three patients stop taking direct-acting oral anticoagulants (DOACs) soon after being prescribed them, researchers find.
18 March 2017

Dabigatran bleeds less frequent but more costly

Dabigatran (Pradaxa) causes less bleeding as a result of over-anticoagulation than warfarin but may be more costly to manage with reversal agents, experience from New Zealand suggests.
03 December 2016

Alert over NSAIDs as use of newer anticoagulants grows

Concerns have been raised about the concomitant use of NSAIDs and novel oral anticoagulants in AF patients.
15 February 2016

Dabigatran antidote given green light by FDA

The first antidote for a novel oral anticoagulant has been approved by the Food and Drug and Drug Administration and is awaiting approval by the TGA.
20 October 2015

Antidotes to newer anticoagulants clear first hurdle

Antidotes for novel oral anticoagulants have shown they can reverse the anticoagulant effects in Phase III trials.
23 June 2015

TGA rejects monitoring for new anticoagulants

Suggestions that novel oral anticoagulants such as dabigatran should have plasma levels monitored have been rejected by the TGA.
04 June 2015

Don’t use aspirin for stroke prevention: cardiologist

Aspirin is still being widely used instead of anticoagulants for stroke prevention because of a misperception that it is an effective “soft option”, a leading cardiologist says.
08 January 2015

Dabigatran bleeding risks shown in real-world data

Two real-world studies on dabigatran have confirmed a lower risk for intracranial bleeding, but have shown that gastrointestinal bleeds may be a problem for older patients.
05 November 2014